Ziel/Aim So far, few studies have specifically investigated volumetric parameters in regard
to their prognostic impact on neuroendocrine tumors (NET). In this study the total
tumor load (TTL), SUVmean and SUVmax, as well as the TL of specific organ systems of NET patients were segmented from
Ga-68-DOTATOC PET/CT and correlated to overall survival (OS) after PRRT.
Methodik/Methods From 81 patients treated with PRRT tumor volumes were generated via a standardized
semi-automatic delineation procedure (PARS; v3.0 Siemens). Segmentation of lesions
above SUVpeak 4 was performed with delineation at 42% SUVpeak and lesions<0,5mL were excluded. Total tumor volumes and tumor volumes from liver,
bones, lymph-nodes, and abdominal TL as well as SUVmean/max were analyzed by Cox regression.
Ergebnisse/Results In addition to automatic segmentation, manual segmentation had to be performed for
2.5% of all lesions. Median OS was 50.7 months, median TTL was 201.27mL, median liver
TL was 165.34mL, median abdominal TL was 12.93mL. The abd. TL was prognostically unfavorable
with a Hazard Ratio (HR) of 1.014 (p=0.016) in the univariate cox regression, whereas
TTL, liver TL, bone TL and lymph-node TL had an HR of close to 1 with non-significant
p values. Analysis of follow up showed that tumor reduction of liver TL had a HR of
0.87 (p=0.015) and the reduction of lymph node TL had a HR of 0.93 (p=0.015) in the
univariate cox regression. The TTL reduction had a HR of 0.57 (p=0.078) in the univariate
cox regression. The multivariate cox regression of TTL, abd. TL, sex, functionality
of tumor, ki67 yielded significant results for the abd. TL (p=0.00013, HR=1.03), sex
(p=0.04, HR=0.3) and ki67 (p=0.03, HR=1.124).
Schlussfolgerungen/Conclusions We show that organ-specific tumor segmentation from PET/CTs results in prognostic
parameters in NET patients. In particular, abd. TL was associated with a shorter OS.
The reduction of liver TL had a positive prognostic effect on OS, which supports the
use of ablative procedures reducing liver tumor mass in liver dominant disease.